VC: Celladon pockets $30M
Free newsletter via e-mail
Celladon pockets $30 million in funds.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Celladon
|
$30M
|
Kleiner Perkins Caufield & Byers |
The funding will enable Celladon to complete preclinical testing and advance Mydicar, its product to improve calcium handling in failing hearts |
|
Domantis
|
$29M
|
Novo Nordisk, MC Life Science Ventures |
The financing will go to developing Domantis' twelve lead programs for treating major diseases including COPD, rheumatoid arthritis, asthma and colorectal cancer |
|
Optimer Pharmaceuticals
|
$22.2M
|
ProQuest Investments |
Money will go to development of PAR-101, a narrow-spectrum antibiotic to treat Clostridium difficile-related diarrhea |
|
Cellartis
|
8M euros
|
Bio Fund Management |
The financing will allow Cellartis to accelerate drug discover and move forward with the company's planned international expansion |
|
Lpath Therapeutics
|
$6M
|
Roaring Fork Capital SBIC |
Proceeds will move the company toward an IND filing of cancer drug Sphingomab and development of second product candidate. |
|
AngioChem
|
$6M
|
BDC Venture Capital |
AngioChem expects to file an IND for the treatment of brain cancer in late 2006. |
SHARE
WITH: